Physician profile
Eric Lavery
NPI 1720059843
$4,062.22
in general payments reported to CMS, 2019-2025
30 companies · $321 in 2025
The $321 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $239 · 2021: $506 · 2022: $1,052 · 2023: $1,229 · 2024: $716 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,051.46 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $543.59 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $419.17 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $344.62 | 2021-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $260.19 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $174.16 | 2023-2024 | Voquezna |
| Celgene Corporation | $164.97 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $126.72 | 2021-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $112.43 | 2020-2024 | Dificid |
| Gilead Sciences, INC. | $98.46 | 2020-2022 | |
| Amgen INC. | $91.83 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $88.51 | 2022-2023 | Linzess |
| Lilly USA, LLC | $61.31 | 2024 | Omvoh |
| Madrigal Pharmaceuticals | $58.96 | 2025 | Rezdiffra |
| Ardelyx, INC. | $54.43 | 2022-2023 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $50.08 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $46.22 | 2021-2023 | Rebyota |
| Pharmacosmos Therapeutics INC. | $45.39 | 2021-2022 | |
| Redhill Biopharma INC. | $40.14 | 2020-2021 | |
| Daiichi Sankyo INC. | $31.37 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $27.53 | 2023 | Dupixent |
| Qol Medical, LLC | $27.22 | 2023 | Sucraid |
| Endo Pharmaceuticals INC. | $24.32 | 2020-2021 | |
| Cumberland Pharmaceuticals, INC. | $22.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.02 | 2024 | Cyltezo |
| Organon LLC | $18.07 | 2021 | |
| Fresenius Kabi USA, LLC | $17.64 | 2023 | Idacio |
| Braintree Laboratories, INC. | $16.41 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.21 | 2022 | |
| Currax Pharmaceuticals LLC | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lavery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.